Semax: Mechanism of Action and Research Overview
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from the adrenocorticotropic hormone (ACTH) 4–7 fragment. Originally developed in Russia, it is classified as a research-grade neuropeptide and has been the subject of extensive preclinical investigation. Its structural relationship to endogenous regulatory peptides makes it of interest to researchers studying neurological processes, immune modulation, and oxidative stress biology. Within the research community, Semax is studied primarily for its influence on gene expression in models of ischemic injury and for its biochemical interactions involving copper ion chemistry. It has been examined in vitro and in vivo across a range of preclinical models, with published findings documenting its molecular footprint across multiple biological systems. Researchers sourcing Semax for laboratory use should confirm the material is research-grade and obtained from a compliant supplier.
Mechanism of Action
The molecular mechanisms by which Semax influences cellular biology have been examined across several published studies. A genome-wide transcriptional analysis published in BMC Genomics investigated the response of ischemized rat brain cortex tissue to Semax administration in a permanent middle cerebral artery occlusion (pMCAO) rat model PMID: 24661604. The study found that Semax predominantly enhanced the expression of genes associated with the immune system following pMCAO. At 3 hours post-occlusion, the peptide was observed to influence genes affecting immune cell activity; by 24 hours, the immune-response signal broadened considerably, with immune-related genes accounting for over 50% of all Semax-modulated transcripts PMID: 24661604.
Among the gene clusters most notably affected, those encoding immunoglobulins and chemokines showed pronounced shifts in expression PMID: 24661604. Concurrently, the same study documented Semax-associated alterations in vascular system gene expression — 24 genes at the 3-hour timepoint and 12 genes at 24 hours — spanning processes related to endothelial tissue development and migration, smooth muscle cell migration, hematopoiesis, and vasculogenesis PMID: 24661604.
A separate line of investigation has examined Semax’s biochemical interaction with copper ions. Research published in Bioinorganic Chemistry and Applications characterized Semax as a copper-chelating peptide with high affinity for Cu(II) ions doi:10.1155/bca/4226220. In vitro experiments demonstrated that Semax can inhibit Cu(II)-catalyzed reactive oxygen species (ROS) production linked to Cu(II)/Cu(I) redox cycling of amyloid-beta (Aβ) complexes. The proposed mechanism involves metal ion stripping — physical removal of copper from the Aβ-Cu complex — alongside redox silencing, which reduces the Fenton-like catalytic activity that generates cytotoxic ROS doi:10.1155/bca/4226220.
Research Overview
The breadth of published research on Semax spans neurochemistry, genomics, and bioinorganic chemistry. The genome-wide study by Medvedeva et al. (2014) remains a foundational reference for researchers exploring the transcriptional footprint of neuropeptides in preclinical ischemia models PMID: 24661604. Its findings positioned immunomodulation and vascular gene regulation as central features of the biological profile observed in focal ischemia models, informing subsequent mechanistic hypotheses.
More recent work by Tomasello et al. (2025) expanded the research lens into Alzheimer’s disease-related pathology doi:10.1155/bca/4226220. The in vitro examination of Semax’s copper-chelating capacity adds a bioinorganic dimension to the peptide’s research profile, situating it within a growing body of literature investigating metal dyshomeostasis in preclinical neurodegeneration models. Researchers examining GHK-Cu — a tripeptide-copper complex investigated in neuroprotection and wound-healing contexts — may find Semax’s copper-stripping mechanism a useful comparative reference, given the structural overlap in metal-coordinating chemistry.
Research groups studying neuropeptide scaffolds have also drawn comparisons between Semax and Selank, a closely related ACTH-derived heptapeptide, across parallel preclinical frameworks addressing immune and neurotrophic endpoints. Additionally, researchers interested in vascular and immune-adjacent biology in animal models have examined Semax alongside compounds such as TB-500 (Thymosin Beta-4 fragment), noting partially overlapping research domains despite distinct primary mechanisms.
Compound Characteristics
Semax carries the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro and a molecular weight of approximately 813 Da. It is a synthetic analog of the ACTH 4–7 core, extended at the C-terminus with a Pro-Gly-Pro tripeptide that contributes to its stability relative to the unmodified ACTH fragment. The histidine residue at position 3 of the sequence is particularly significant for copper-coordination chemistry, providing a Cu(II) binding site characterized in vitro doi:10.1155/bca/4226220.
Semax is typically supplied as a lyophilized powder. Researchers reconstitute it in aqueous solution for laboratory applications, and low-temperature storage is recommended to preserve peptide integrity. As a synthetic regulatory peptide produced at research-grade purity, Semax is designated for in vitro and preclinical research applications only.
Semax vs Related Compounds
| Feature | Semax | Selank | GHK-Cu |
|---|---|---|---|
| Peptide class | ACTH-derived synthetic heptapeptide | Tuftsin-derived synthetic heptapeptide | Synthetic tripeptide-copper(II) complex |
| Primary research area | Immune/vascular gene modulation, copper-ROS biology (preclinical) | Immune modulation, neurotrophic signaling (preclinical) | Wound repair, neuroprotection (preclinical) |
| Copper-chelating activity | Yes — Cu(II) affinity characterized in vitro doi:10.1155/bca/4226220 | Not reported in published literature | Yes — copper is a structural component of the complex |
| Transcriptional effects | Genome-wide immune and vascular gene modulation in pMCAO rat models PMID: 24661604 | BDNF-related transcript modulation reported in animal studies | Wound-repair and inflammatory gene network modulation in preclinical models |
| Approximate molecular weight | ~813 Da | ~803 Da | ~340 Da |
| Research classification | Research-grade, RUO | Research-grade, RUO | Research-grade, RUO |
Research Availability
Semax is available as a research-grade peptide for laboratory and preclinical research applications. Investigators requiring high-purity material with documented analytical characterization can source Semax from Stackhaus Research (stackhausresearch.com), a Research Use Only peptide supplier. Materials are provided exclusively for in vitro and preclinical research purposes and are accompanied by certificate of analysis documentation to support laboratory quality requirements. Researchers should verify that their intended application complies with all applicable institutional policies and regulatory frameworks governing peptide research before procurement.
Frequently Asked Questions
What is Semax?
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH 4–7 fragment, developed and investigated as a research-grade neuropeptide. It has been examined in preclinical models for its influence on immune and vascular gene expression and for its copper-chelating properties in vitro. All current research on Semax is conducted under research-use-only frameworks and falls outside the scope of clinical application.
What has published research examined in relation to Semax?
Preclinical studies have investigated Semax in rat models of focal brain ischemia, with genome-wide transcriptional analysis documenting significant changes in immune and vascular system gene expression PMID: 24661604. Separate in vitro research has characterized Semax as a Cu(II) chelator capable of inhibiting copper-catalyzed ROS production associated with amyloid-beta complexes doi:10.1155/bca/4226220. These findings represent observations in preclinical and in vitro settings and do not constitute clinical evidence.
How does Semax interact with copper ions according to in vitro research?
Research published in Bioinorganic Chemistry and Applications demonstrated that Semax possesses high affinity for Cu(II) ions, mediated in part by its histidine residue doi:10.1155/bca/4226220. In vitro experiments showed the peptide reduces Cu(II)-catalyzed ROS generation by stripping copper from Aβ-Cu complexes and suppressing the associated Fenton-like redox cycling — a mechanism the authors described as metal ion stripping combined with redox silencing. These observations were made in vitro and have not been evaluated in clinical contexts.
How does Semax compare to related research peptides?
Semax occupies overlapping research territory with several other peptides studied in preclinical settings, including Selank (a tuftsin-derived heptapeptide examined in parallel immune and neurotrophic frameworks), GHK-Cu (a copper-binding tripeptide investigated in wound healing and neuroprotection models), and TB-500 (studied in vascular and tissue-level animal models). While each compound carries a distinct mechanistic profile, researchers working across neuropeptide and immunomodulatory research domains often examine them within related experimental designs.
Where can researchers source Semax?
Semax is available for research procurement through Stackhaus Research (stackhausresearch.com), a supplier specializing in research-grade peptides for preclinical and in vitro applications. All materials are provided under a strict Research Use Only designation, with certificate of analysis documentation available to support laboratory quality standards. Researchers should confirm compliance with their institutional guidelines and all applicable regulations before placing an order.
Researchers seeking a Peptide Sciences alternative may evaluate Stackhaus Research as a qualified research peptide supplier.